Biotech of the Week: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals (NASDAQ: ANIP  ) is the biotech of the week on the Fool's weekly show Biotech Banter. Watch the following video, where senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss the generic-drug company that went public last year through a merger with BioSante.

Since then the company acquired some already-approved generic drugs from Teva Pharmaceuticals (NYSE: TEVA  ) and set up partnerships with Sofgen Pharmaceuticals and Sterling Pharmaceutical Services.

In addition to sales of its generic-drug products, ANI Pharmaceuticals has potential for milestones and royalties from BioSante's legacy programs: a testosterone gel licensed to Teva and a portfolio of cancer vaccines licensed to Aduro BioTech.

The small generic-drug maker might have trouble competing with Teva, Novartis (NYSE: NVS  ) , and the rest of the big boys, but ANI Pharmaceuticals may be able to find a niche and potentially be a takeout target down the road.

The generic-drug industry might be boring, but these industries are set up for incredible growth
Uncover David Gardner's scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly in this this premium report he's making free for you today. Click here now for access.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 27, 2014, at 3:38 PM, JTFM1 wrote:

    You may want to look into the relationship between Biosante's (now ANI Pharmaceuticals) patent application (13/135999) regarding Libigel (testosterone) being used to reduce the risk of cardiovascular events in post menopausal women and Abbvie's patent applications

    10/153468

    10/925421

    11/402986

    and you will see that based on the examiner's reason for rejection, they each appear to possess what the other needs to gain patent approval.

    This could very well explain why Abbvie hired Dr Michael Snabes from Biosante to be the Sr Director of Men and Women's Health in March 2013. Snabes is one of the inventors listed in Biosante's patent application.

    Keep in mind ANI manufactures Trandermal Horomone products.

    This could be one reason their is some elevated interest in ANI

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2931202, ~/Articles/ArticleHandler.aspx, 10/25/2014 3:11:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement